U.S. Markets closed

CLASS ACTION UPDATE for FTCH, CVET, MYGN and YJ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Farfetch Limited  (FTCH)
Class Period:
all persons and entities who purchased or otherwise acquired Farfetch Class A ordinary shares between September 21, 2018, and August 8, 2019, inclusive, including those who purchased or otherwise acquired Farfetch Class A ordinary shares pursuant and/or traceable to the registration statement and prospectus issued in connection with Company's September 21, 2018 initial public offering.
Lead Plaintiff Deadline: November 18, 2019
Join the action: https://www.zlk.com/pslra-1/farfetch-loss-form?wire=3&prid=4397

About the lawsuit: During the class period, Farfetch Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company would refuse to reduce merchandise prices to match the rest of the market; (2) this sub-optimal pricing strategy rendered the Company's platform highly susceptible to underpricing by competitors, despite what Defendants touted as a "superior" platform; and (3) as a result, the Company's past and projected Platform Gross Merchandise Value growth rates were foreseeably unsustainable. As a result of the foregoing, Defendants' statements about the Company's business strategy and growth prospects lacked a reasonable basis at all relevant times.

To learn more about the Farfetch Limited  class action contact jlevi@levikorsinsky.com.

Covetrus, Inc. (CVET)
Class Period:
February 8, 2019 - August 12, 2019
Lead Plaintiff Deadline: November 29, 2019
Join the action: https://www.zlk.com/pslra-1/covetrus-inc-loss-form?wire=3&prid=4397

About the lawsuit: Covetrus, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company’s separation from Henry Schein.

To learn more about the Covetrus, Inc. class action contact jlevi@levikorsinsky.com.

Myriad Genetics, Inc. (MYGN)
Class Period:
September 2, 2016 - August 13, 2019
Lead Plaintiff Deadline: November 26, 2019
Join the action: https://www.zlk.com/pslra-1/myriad-genetics-inc-loss-form?wire=3&prid=4397

About the lawsuit: Myriad Genetics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company’s revenue; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Myriad Genetics, Inc. class action contact jlevi@levikorsinsky.com.

Yunji Inc. (YJ)
Class Period:
on behalf of shareholders who purchased or otherwise acquired Yunji American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s May 2019 initial public offering.
Lead Plaintiff Deadline: January 13, 2020
Join the action: https://www.zlk.com/pslra-1/yunji-inc-loss-form?wire=3&prid=4397

About the lawsuit: During the class period, Yunji Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was shifting certain of its sales to its marketplace platform; (2) this supply chain restructuring was likely to disrupt Yunji’s relationships with suppliers; (3) this supply chain restructuring was likely to have an adverse impact on the Company’s financial results; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the Yunji Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com